The genotype of these samples was unknown, but about 90% of pancreatic cancer patients and about a 20% of NSCLC patients harbor KRAS mutations.11 Calibration lines were established for 6 of the main mutations and other RAS forms.34 For every sample, we were able to detect and measure WT KRAS (Fig. 3), and to the best of our knowledge, this is the first occasion that the gene product of KRAS has been measured in cancer patient plasma using LC-SRM. The gene discussed is KRAS; the disease is cancer.